Ozempic and Weight-Loss Injections: What We Need to Talk About Beyond Weight Loss
By now, you probably know someone taking a weight-loss injection like Ozempic.
Maybe they've lost weight. Maybe they've told you their food noise has disappeared. Maybe you've wondered if it could help you too.
GLP-1 medications have become a huge part of the conversation about weight, appetite and health. And while there's growing evidence about their effects, there's another side to the conversation that deserves much more attention.
Are people receiving appropriate assessments before they're prescribed these medications? Are the risks and side effects being discussed properly? And what happens when someone has a history of binge eating, restrictive dieting or an eating disorder?
As a registered dietitian specialising in binge eating, these are questions I think we need to be asking.
I believe in body autonomy. Whether someone chooses to take a GLP-1 medication is a personal decision to make with an appropriately qualified healthcare professional.
My concern isn't with judging individual choices. It's with a healthcare and online prescribing landscape where access, screening and ongoing support may not always be what they need to be.
So, let's look beyond the weight-loss headlines and explore what we know, what we're still learning, and what deserves more attention.
First, what are Ozempic and GLP-1 medications?
When people talk about Ozempic, they're often referring to GLP-1 medications more broadly.
Ozempic contains semaglutide and is licensed to help manage type 2 diabetes. Wegovy contains the same active ingredient but is licensed for weight management in eligible patients. Other medications, including tirzepatide (Mounjaro), work on related hormone pathways.
These medications affect appetite and how the body regulates blood glucose. They can reduce hunger and help people feel satisfied with less food.
For some people, they also have important health benefits when prescribed for an appropriate indication.
But these are prescription medications, not risk-free shortcuts to weight loss. They need appropriate assessment, clear information about potential risks and suitable follow-up.
And that's where some of the current concerns begin.
1. Is access to weight-loss injections being managed safely?
One of the biggest concerns is whether everyone receiving these medications is being assessed thoroughly enough.
In May 2026, UK consumer organisation Which? reported an undercover investigation in which four online pharmacies supplied weight-loss injections after the investigator provided false health information and fake GP details.
This doesn't tell us how common inappropriate prescribing is across the whole industry. However, it raises important questions about how some online services verify information and assess whether treatment is appropriate.
A separate study published in 2026, involving simulated patients approaching 49 online prescribing websites in the United States, also found substantial gaps in clinical oversight. Screening practices varied, and fewer than six in ten websites asked about eating-disorder history.
These findings matter because a questionnaire and a prescription aren't necessarily a substitute for a thorough clinical assessment.
People may access these medications through different healthcare systems, and prescribing rules vary by country. The eligibility criteria and safeguards also differ between products and services. But wherever treatment is prescribed, the person's medical history, current health and individual circumstances need to be taken seriously.
There have also been reports of people misrepresenting their weight or medical history to obtain medication. In some cases, people may feel pressure to do this because they believe weight loss is essential, or because they fear they won't qualify otherwise.
I don't think we should assume that everyone taking these medications has bypassed appropriate checks. Equally, we shouldn't ignore evidence that some systems may make it too easy for important information to be missed.
Access to medication should come with appropriate assessment and support, not just the ability to obtain a prescription.
2. What if you have a history of binge eating or an eating disorder?
This is particularly important to me as a binge eating dietitian.
People with a history of an eating disorder or disordered eating may have complicated relationships with food, appetite, body image and weight. Some may have spent years restricting their food intake, feeling frightened of weight gain or struggling with cycles of dieting and binge eating.
If you're considering a GLP-1 medication, this history is important information for your prescriber to know.
That doesn't mean everyone with a history of an eating disorder will automatically be unsuitable for these medications. Decisions need to be individualised, and the evidence about GLP-1 medications as treatments for people with eating disorders is still developing.
However, appetite suppression and significant changes in eating can create particular challenges for some people who are vulnerable to restrictive eating or nutritional inadequacy.
If someone is already struggling to eat enough, for example, experiencing less hunger could make it easier to miss meals or ignore their body's needs. Someone who has previously experienced an eating disorder may also find that weight loss or the ability to eat less reinforces old beliefs about what their body should look like or how little they should eat.
There have been reports of people with eating-disorder histories receiving these medications without adequate screening. These reports are concerning, but they don't establish how frequently this happens across all prescribing services.
The point is that a history of disordered eating should not be overlooked simply because someone meets a weight-based eligibility criterion.
A thorough assessment should consider the whole person, including their physical health, relationship with food, mental wellbeing and any previous or current eating difficulties.
3. What are the side effects?
GLP-1 medications can cause side effects, and it's important to understand the potential risks before starting treatment.
Common side effects include gastrointestinal symptoms such as nausea, vomiting, diarrhoea, constipation and abdominal discomfort. For some people, these symptoms are mild or improve over time. For others, they can make eating and drinking enough more difficult.
This matters because eating significantly less isn't automatically the same as meeting your nutritional needs.
If nausea, early fullness or reduced appetite makes it difficult to eat regularly, you may struggle to get enough energy, protein, fibre, vitamins, minerals and fluids. Some people may need additional nutritional support to help maintain adequate intake.
There are also less common but potentially serious risks.
In January 2026, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) strengthened warnings about acute pancreatitis, including rare reports of severe, necrotising and fatal cases associated with GLP-1 and related medications.
In February 2026, the MHRA also updated its guidance on semaglutide following evidence of a very rare risk of a serious eye condition called non-arteritic anterior ischaemic optic neuropathy (NAION), which can cause sudden vision loss.
These risks are not experienced by everyone, and a reported adverse event does not automatically prove that a medication caused it. The overall benefits and risks depend on the individual and the reason the medication is prescribed.
However, these are not details to dismiss because a medication is popular or because someone has seen positive results online.
If you're taking a GLP-1 medication, make sure you understand the information provided with your prescription and know when to seek medical advice. Severe, persistent abdominal pain, particularly if it spreads to your back, needs urgent medical assessment. Sudden or rapidly worsening vision changes also require urgent assessment.
You can find the MHRA's updated guidance on pancreatitis and its guidance on semaglutide and NAION.
4. What happens when you stop taking the medication?
Another important consideration is what happens when treatment ends.
In an extension of the STEP 1 trial, researchers followed participants after they stopped semaglutide. On average, participants regained around two-thirds of the weight they had previously lost over the following year.
This doesn't mean the medication never worked or that everyone will experience the same outcome. It does show that weight regain is common after treatment stops and that the longer-term picture needs to be considered from the beginning.
Before starting treatment, it is worth discussing how long you might take it, whether it is financially sustainable, what follow-up you will receive and what support is available if your appetite changes or weight regain occurs.
For someone with a history of disordered eating, the fear of regaining weight may also be particularly difficult. It can bring back the feeling that weight must be controlled at all costs, potentially leading to more restriction or renewed dieting.
These are important conversations to have before treatment begins, rather than waiting until someone is struggling.
5. What about food noise and binge eating?
One reason GLP-1 medications attract attention from people who struggle with binge eating is the possibility of experiencing less food noise.
Food noise is a term people use to describe frequent or persistent thoughts about food, eating, cravings and what they should or shouldn't eat.
Some people taking GLP-1 medications report thinking about food less often, feeling satisfied sooner or experiencing fewer urges to eat.
For someone who has spent years feeling consumed by thoughts about food, that change may feel like a huge relief.
Early research has also explored whether GLP-1 medications could reduce binge-eating symptoms for some people. However, the evidence remains limited, and more high-quality research is needed before we can draw firm conclusions about their role in treating binge eating disorder.
We also need to distinguish between experiencing fewer urges to eat and recovering from binge eating.
Binge eating can involve much more than appetite. It may be connected to restrictive dieting, irregular eating, emotional regulation, ADHD, body dissatisfaction, shame and rigid food rules.
A medication may change appetite, but it doesn't automatically help someone challenge the belief that carbohydrates are bad, feel comfortable eating previously feared foods, cope with difficult emotions or stop feeling guilty after eating.
Changing appetite and changing your relationship with food are not necessarily the same thing.
Both may matter, but one doesn't guarantee the other.
6. Can appetite suppression make restrictive eating worse?
For some people, reduced appetite can make it easier to eat less than their body needs.
If you've spent years dieting, you may already have learned to ignore hunger, skip meals or see eating less as a sign of success.
When a medication reduces hunger, those behaviours may feel easier to continue. You might find yourself missing meals because you're not hungry, feeling pleased that you can go longer without eating, or becoming anxious about the possibility of your appetite returning.
This isn't inevitable for everyone taking a GLP-1 medication. But it's an important possibility to consider, particularly for people with a current or previous eating disorder or a pattern of restrictive eating.
Eating enough consistently is important for physical health, and prolonged under-eating can have consequences even if someone is losing weight.
If you're finding it difficult to eat enough, feeling increasingly anxious about food or becoming preoccupied with keeping your appetite low, speak with your prescribing clinician. You may also benefit from support from a dietitian experienced in eating disorders.
You deserve care that considers your nutritional needs and mental wellbeing, not just changes on the scales.
7. What should we be asking before starting a GLP-1 medication?
Rather than focusing only on how much weight someone might lose, I think we need to ask better questions about the quality of care surrounding these medications.
If you're considering treatment, you might ask:
Is this medication appropriate for me? Has my medical history and current health been properly assessed?
Have I discussed my relationship with food? Does my prescriber know about any current or previous binge eating, restrictive eating or eating disorder?
What are the risks for me? Have I been given clear information about side effects, warning signs and when to seek medical advice?
How will I make sure I'm eating enough? What support is available if nausea, early fullness or reduced appetite affects my intake?
What follow-up will I receive? Who can I contact if I'm struggling physically or psychologically?
What happens if I stop treatment? Have we discussed ongoing care, changes in appetite and the possibility of weight regain?
You should feel able to answer these questions without being made to feel difficult or demanding. A prescription should be part of a wider plan for your health, with space to discuss concerns honestly.
So, are GLP-1 medications good or bad?
I don't think that's the most useful question.
These medications can have meaningful benefits for some people when prescribed appropriately. They can also cause side effects, create nutritional challenges and raise particular concerns for people vulnerable to disordered eating.
What matters is whether the medication is appropriate for the individual, whether they understand the potential benefits and risks, and whether they receive proper assessment and ongoing support.
I don't want people to feel ashamed for taking a GLP-1 medication, and I don't want people to feel pressured into taking one because weight loss is presented as the answer to every health concern.
I also don't want the excitement surrounding these medications to distract us from the importance of safe prescribing, honest medical histories and careful consideration of eating-disorder risk.
As a binge eating dietitian, I want people to know that they deserve support with their relationship with food, whatever medication they do or don't take.
If you experience fewer binge episodes while taking a medication, that may feel significant. But if you still struggle with food guilt, restriction, body dissatisfaction or fear of weight gain, those experiences deserve attention too.
You don't have to wait until your appetite changes or your weight changes to seek support.
Your health is about more than your weight, and your relationship with food deserves care in its own right.
References and further reading
Rubino, D. et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28, 2083–2091. Read the study.
Wilding, J. P. H. et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. Read the study.
Which? (2026). The online pharmacies selling weight-loss jabs inappropriately. Read the investigation.
MHRA (2026). GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis. Read the safety update.
MHRA (2026). Updated guidance for semaglutide prescribers and patients regarding the very rare risk of NAION. Read the safety update.
Lincoff, A. M. et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389, 2221–2232. Read the study.
Ready To Break Free From Binge Eating?
Hi, I'm Toni, The Binge Dietitian.
I help women who are stuck in the cycle of dieting, binge eating, and starting over every Monday build a calmer, more balanced relationship with food.
Together, we'll work on reducing binge eating, letting go of food rules, and helping you feel more confident around all foods without relying on willpower, restriction, or another diet.
If you're tired of thinking about food all day and ready for a different approach, I'd love to support you.
